Skip to main content
Subgroup Analysis of CANDOR-Evaluated Outcomes with Carfilzomib plus Dexamethasone and Daratumumab Based on Cytogenetic Risk
Read More
First Results from a Phase 1 Study of BMS-986393, a GPRC5D-Targeted CAR T-Cell Therapy, in Patients with RRMM
Read More
Subcutaneous Isatuximab Administration by an On-Body Delivery System May Provide a More Convenient Option for Patients with RRMM
Read More
Anti-CD38 Antibodies in the Treatment of RRMM: Considerations for Pharmacists
Read More
Multiple Myeloma
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in High-Risk Multiple Myeloma Patients: Interim Analysis of the GMMG-CONCEPT Trial
Read More
Multiple Myeloma
Evaluating Maintenance Treatments in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review
Read More
Multiple Myeloma
Iberdomide, a Cereblon E3 Ligase Modulator, plus Dexamethasone Demonstrated Activity in Heavily Pretreated Patients with Multiple Myeloma
Read More
Multiple Myeloma
Once-Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma: The SKylaRk Trial
Read More
Multiple Myeloma
Patient-Reported Outcomes of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone
Read More
Multiple Myeloma
Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma with No Prior BCMA-Targeted Treatment: Results from MagnetisMM-3
Read More
Page 43 of 200
Results 421 - 430 of 1993